Corticosteroids for Post-Extubation Dysphagia
Randomized Trial of Corticosteroids for Post-Extubation Aspiration
University of Colorado, Denver
80 participants
Nov 13, 2024
INTERVENTIONAL
Conditions
Summary
This is a placebo-controlled, double-blind randomized trial of a short course of intravenous corticosteroids for Acute Respiratory Failure Survivors with Fiberoptic Endoscopic Evaluation of Swallowing (FEES) documented laryngeal edema. Study was leveraged using the existing R01 grant infrastructure COMIRB # 21-3873, study design, and research methods. Patients for the study proposed will have already been enrolled in the R01 longitudinal cohort study. The sites to perform this study include Colorado, BU, Yale, and Stanford. Those R01-enrolled patients with laryngeal edema on their initial FEES examination: defined as the revised Patterson edema score greater than zero, will be approached for enrollment.
Eligibility
Inclusion Criteria5
- Participant enrolled in primary study COMIRB #21-3873/ NCT # 05108896
- Laryngeal edema identified on participants primary study Fiberoptic Endoscopic Evaluation of Swallowing (FEES) as defined as a revised Patterson edema score greater than zero
- Admission to an ICU during their hospitalization
- Mechanical ventilation with an endotracheal tube for greater than 48 hours.
- Extubation except for compassionate extubation or transition to end-of-life care.
Exclusion Criteria12
- Patient or provider refusal
- Contraindication or corticosteroids defined as an allergic reaction (extremely rate) or taking other immunosuppressive medications.
- Chronic treatment with corticosteroids (>= 40 mg Prednisone/day, >=32 Methylprednisolone/day)
- Contraindication to enteral/oral nutrition administration.
- Pre-existing history of dysphagia or aspiration.
- Pre-existing or acute primary central or peripheral neuromuscular disorder.
- Presence of a chronic tracheostomy (present prior to ICU admission).
- Pre-existing head and neck cancer or surgery.
- Coagulopathy resulting in uncontrolled nasal or pharyngeal bleeding.
- Delirium as assessed by CAM-ICU
- Inability to obtain informed consent from patient or an appropriate surrogate.
- Age <18 years.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
Normal Saline placebo IV every 6 hours for 4 doses
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06670521